Published :
Report ID:
Pages :
Format :
The Global mRNA Vaccines Andtherapeutics Market Was Valued At USD 707.97 Million In 2022 And Is Projected To Reach USD 12.1 Billion By 2030, At A CAGR Of 1.7% From 2023 To 2030.
mRNA Vaccines & Therapeutics Market Overview:
An mRNA vaccine is a nucleic acid-based vaccine containing messenger RNA that causes a patient's cells to produce proteins as part of a treatment option. This vaccine has self-regulating properties. mRNA vaccines use host cellular machinery to translate mRNA into corresponding antigens to generate an effective immune response. The application of mRNA vaccines eliminates the risk of producing infectious particles in the body. Messenger ribonucleic acid (mRNA) refers to a single protein-coding gene in the genome that serves as the basis for protein synthesis within the cell. mRNA vaccines and RNAi therapeutics combine desirable immunological properties and are produced in the laboratory using mammalian cells. Some common types of vaccines and therapies include self-amplifying, non-replicating, self-replicating in vivo, and non-replicating dendritic cell mRNAs in vitro. They are injected into the body to trigger immune sensors that detect the virus and produce viral antigenic proteins inside the cells. This helps boost the body's immunity by improving B-cell and T-cell responses. The market for mRNA vaccines is gaining traction due to its growing popularity, as it offers many advantages over other nucleic acid-based vaccines. mRNA vaccines can be produced quickly and cheaply, thus boosting market demand. The Global mRNA Vaccines Market report provides a holistic assessment of the market. The report provides a comprehensive analysis of the key segments, trends, drivers, constraints, competitive landscape, and factors that play an important role in the market.
mRNA Vaccines & Therapeutics market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (million USD), with historical and forecast data for the period 2017 to 2030, with 2022 being considered as the base year. This report segments the global mRNA Vaccines & Therapeutics market in detail. Regional market sizes related to products by type, by application, and by the player are also delivered. In estimating the size of the market, we took into account the impact of COVID-19 and the Russian-Ukraine war.
Key Market Updates:
Major Segments Covered in the Global mRNA Vaccines & Therapeutics Market:
Market Key Players:
Argos Therapeutics, AstraZeneca, Bayer, BioNTech, Boehringer Ingelheim, CRISPR Therapeutics, CureVac, eTheRNA immunotherapies, Ethris, GlaxoSmithKline Vaccines, In-Cell-Art, Intellia Therapeutics, Janssen, Kernal Biologics, MaxCyte, Moderna Therapeutics, Novartis, PhaseRx, Precision NanoSystems, RaNa Therapeutics., And Others.
mRNA Vaccines & Therapeutics Market by Types:
mRNA Vaccines & Therapeutics Market by Applications:
mRNA Vaccines & Therapeutics Market by Regions:
The report estimates revenue growth at the worldwide, regional, and country levels and delivers an analysis of the recent industry trends in each sub-segment from 2017 to 2030
North America will dominate the market with a share of over 5.0% in 2021 and will be the fastest growing region during the forecast period. Availability of substantial research funding, expansion of federal programs to develop RNA-based drugs, and increasing number of clinical trials will drive the North American market. For example, in November 2020, the National Institutes of Health (NIH), the Department of Defense, and federally funded academic laboratories all supported the basic research of Graham et al., which is an important part of the rapid development of a COVID-19 vaccine. Since the start of the pandemic, the government has invested an additional $10.5 billion in vaccine makers to speed up the delivery of their products.
Significant Market Dynamics:
This market growth is driven by chronic diseases such as cancer, heart disease, respiratory diseases, CKD, and rare diseases such as propionic acidemia, methylmalonic acidemia, glycogen disease, phenylketonuria, and metabolic and immune disorders. Driven by rising prevalence. For example, according to Globocan, in December 2020, there were 19. million new cancer cases and 10 million cancer-related deaths worldwide. In addition, the popularity of mRNA vaccines, the development of personalized cancer treatments, and new Strong pipeline of products increase demand for mRNA vaccines and therapeutics, thereby driving industry growth during the forecast period.
Increased investments by operators to produce advanced and effective therapeutics and vaccines are likely to support industry growth throughout the projected time frame. For example, in April 2021, U.S. mRNA therapeutics developer Arcturus Therapeutics formed a joint venture with Axcelead, Inc. to establish a Japanese company in Chiba Prefecture and is building a production facility in Minamisoma City, Fukushima Prefecture. Such investments are likely to complement industry growth in the coming years.
Report Scope of Global mRNA Vaccines & Therapeutics Market:
Report Attribute | Details |
Study Period | 2017-2030 |
Base Year | 2022 |
Estimated year | 2023 |
Forecast period | 2023-2030 |
Historic Period | 2017-2022 |
Units | Value (USD Billion) |
Growth Rate | CAGR of 1.7% from 2023 to 2030 |
By Type |
|
By Application |
|
By Treatment Type: |
|
By Companies |
Argos Therapeutics, AstraZeneca, Bayer, BioNTech, Boehringer Ingelheim, CRISPR Therapeutics, CureVac, eTheRNA immunotherapies, Ethris, GlaxoSmithKline Vaccines, In-Cell-Art, Intellia Therapeutics, Janssen, Kernal Biologics, MaxCyte, Moderna Therapeutics, Novartis, PhaseRx, Precision NanoSystems, RaNa Therapeutics., And Others. |
|
|
Reasons to Purchase this Report |
|
Points Covered in the Report
Any special requirements about this report, please let us know and we can provide a custom report.
Note – In order to provide a more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19 and the Russia-Ukraine war.